A novel lead compound CM-118

References

• Krause DS, Van Etten RA. Tyrosine kinases as targets for cancer therapy. N Engl J Med 2005; 353:172 - 87; http://dx.doi.org/10.1056/NEJMra044389; PMID: 16014887
   PubMed Web of Science ®Google Scholar
• Weinstein IB, Joe AK. Mechanisms of disease: Oncogene addiction--a rationale for molecular targeting in cancer therapy. Nat Clin Pract Oncol 2006; 3:448 - 57; http://dx.doi.org/10.1038/ncponc0558; PMID: 16894390
   PubMedGoogle Scholar
• O’Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F, Cornelissen JJ, Fischer T, Hochhaus A, Hughes T, et al, IRIS Investigators. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003; 348:994 - 1004; http://dx.doi.org/10.1056/NEJMoa022457; PMID: 12637609
   PubMed Web of Science ®Google Scholar
• Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344:783 - 92; http://dx.doi.org/10.1056/NEJM200103153441101; PMID: 11248153
   PubMed Web of Science ®Google Scholar
• Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, Campos D, Maoleekoonpiroj S, Smylie M, Martins R, et al, National Cancer Institute of Canada Clinical Trials Group. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005; 353:123 - 32; http://dx.doi.org/10.1056/NEJMoa050753; PMID: 16014882
   PubMed Web of Science ®Google Scholar
• Morales La Madrid A, Campbell N, Smith S, Cohn SL, Salgia R. Targeting ALK: a promising strategy for the treatment of non-small cell lung cancer, non-Hodgkin’s lymphoma, and neuroblastoma. Target Oncol 2012; 7:199 - 210; http://dx.doi.org/10.1007/s11523-012-0227-8; PMID: 22968692
   PubMed Web of Science ®Google Scholar
• Shaw AT, Yasothan U, Kirkpatrick P. Crizotinib. Nat Rev Drug Discov 2011; 10:897 - 8; http://dx.doi.org/10.1038/nrd3600; PMID: 22129984
   PubMed Web of Science ®Google Scholar
• Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solomon B, Maki RG, Ou SH, Dezube BJ, Jänne PA, Costa DB, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010; 363:1693 - 703; http://dx.doi.org/10.1056/NEJMoa1006448; PMID: 20979469
   PubMed Web of Science ®Google Scholar
• Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, Ishikawa S, Fujiwara S, Watanabe H, Kurashina K, Hatanaka H, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007; 448:561 - 6; http://dx.doi.org/10.1038/nature05945; PMID: 17625570
   PubMed Web of Science ®Google Scholar
• Rikova K, Guo A, Zeng Q, Possemato A, Yu J, Haack H, Nardone J, Lee K, Reeves C, Li Y, et al. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell 2007; 131:1190 - 203; http://dx.doi.org/10.1016/j.cell.2007.11.025; PMID: 18083107
   PubMed Web of Science ®Google Scholar
• Morris SW, Kirstein MN, Valentine MB, Dittmer KG, Shapiro DN, Saltman DL, Look AT. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin’s lymphoma. Science 1994; 263:1281 - 4; http://dx.doi.org/10.1126/science.8122112; PMID: 8122112
   PubMed Web of Science ®Google Scholar
• Griffin CA, Hawkins AL, Dvorak C, Henkle C, Ellingham T, Perlman EJ. Recurrent involvement of 2p23 in inflammatory myofibroblastic tumors. Cancer Res 1999; 59:2776 - 80; PMID: 10383129
   PubMed Web of Science ®Google Scholar
• Mossé YP, Laudenslager M, Longo L, Cole KA, Wood A, Attiyeh EF, Laquaglia MJ, Sennett R, Lynch JE, Perri P, et al. Identification of ALK as a major familial neuroblastoma predisposition gene. Nature 2008; 455:930 - 5; http://dx.doi.org/10.1038/nature07261; PMID: 18724359
   PubMed Web of Science ®Google Scholar
• Janoueix-Lerosey I, Lequin D, Brugières L, Ribeiro A, de Pontual L, Combaret V, Raynal V, Puisieux A, Schleiermacher G, Pierron G, et al. Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma. Nature 2008; 455:967 - 70; http://dx.doi.org/10.1038/nature07398; PMID: 18923523
   PubMed Web of Science ®Google Scholar
• Chen Y, Takita J, Choi YL, Kato M, Ohira M, Sanada M, Wang L, Soda M, Kikuchi A, Igarashi T, et al. Oncogenic mutations of ALK kinase in neuroblastoma. Nature 2008; 455:971 - 4; http://dx.doi.org/10.1038/nature07399; PMID: 18923524
   PubMed Web of Science ®Google Scholar
• George RE, Sanda T, Hanna M, Fröhling S, Luther W 2nd, Zhang J, Ahn Y, Zhou W, London WB, McGrady P, et al. Activating mutations in ALK provide a therapeutic target in neuroblastoma. Nature 2008; 455:975 - 8; http://dx.doi.org/10.1038/nature07397; PMID: 18923525
   PubMed Web of Science ®Google Scholar
• Carén H, Abel F, Kogner P, Martinsson T. High incidence of DNA mutations and gene amplifications of the ALK gene in advanced sporadic neuroblastoma tumours. Biochem J 2008; 416:153 - 9; http://dx.doi.org/10.1042/BJ20081834; PMID: 18990089
   PubMed Web of Science ®Google Scholar
• Christensen JG, Zou HY, Arango ME, Li Q, Lee JH, McDonnell SR, Yamazaki S, Alton GR, Mroczkowski B, Los G. Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma. Mol Cancer Ther 2007; 6:3314 - 22; http://dx.doi.org/10.1158/1535-7163.MCT-07-0365; PMID: 18089725
   PubMed Web of Science ®Google Scholar
• Gherardi E, Birchmeier W, Birchmeier C, Vande Woude G. Targeting MET in cancer: rationale and progress. Nat Rev Cancer 2012; 12:89 - 103; http://dx.doi.org/10.1038/nrc3205; PMID: 22270953
   PubMed Web of Science ®Google Scholar
• Peters S, Adjei AA. MET: a promising anticancer therapeutic target. Nat Rev Clin Oncol 2012; 9:314 - 26; http://dx.doi.org/10.1038/nrclinonc.2012.71; PMID: 22566105
   PubMed Web of Science ®Google Scholar
• Schmidt L, Junker K, Nakaigawa N, Kinjerski T, Weirich G, Miller M, Lubensky I, Neumann HP, Brauch H, Decker J, et al. Novel mutations of the MET proto-oncogene in papillary renal carcinomas. Oncogene 1999; 18:2343 - 50; http://dx.doi.org/10.1038/sj.onc.1202547; PMID: 10327054
   PubMed Web of Science ®Google Scholar
• Soman NR, Correa P, Ruiz BA, Wogan GN. The TPR-MET oncogenic rearrangement is present and expressed in human gastric carcinoma and precursor lesions. Proc Natl Acad Sci U S A 1991; 88:4892 - 6; http://dx.doi.org/10.1073/pnas.88.11.4892; PMID: 2052572
   PubMed Web of Science ®Google Scholar
• Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO, Lindeman N, Gale CM, Zhao X, Christensen J, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007; 316:1039 - 43; http://dx.doi.org/10.1126/science.1141478; PMID: 17463250
   PubMed Web of Science ®Google Scholar
• Turke AB, Zejnullahu K, Wu YL, Song Y, Dias-Santagata D, Lifshits E, Toschi L, Rogers A, Mok T, Sequist L, et al. Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC. Cancer Cell 2010; 17:77 - 88; http://dx.doi.org/10.1016/j.ccr.2009.11.022; PMID: 20129249
   PubMed Web of Science ®Google Scholar
• Ebos JM, Lee CR, Cruz-Munoz W, Bjarnason GA, Christensen JG, Kerbel RS. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 2009; 15:232 - 9; http://dx.doi.org/10.1016/j.ccr.2009.01.021; PMID: 19249681
   PubMed Web of Science ®Google Scholar
• Sennino B, Ishiguro-Oonuma T, Wei Y, Naylor RM, Williamson CW, Bhagwandin V, Tabruyn SP, You WK, Chapman HA, Christensen JG, et al. Suppression of tumor invasion and metastasis by concurrent inhibition of c-Met and VEGF signaling in pancreatic neuroendocrine tumors. Cancer Discov 2012; 2:270 - 87; http://dx.doi.org/10.1158/2159-8290.CD-11-0240; PMID: 22585997
   PubMed Web of Science ®Google Scholar
• Sennino B, Ishiguro-Oonuma T, Schriver BJ, Christensen JG, McDonald DM. Inhibition of c-Met reduces lymphatic metastasis in RIP-Tag2 transgenic mice. Cancer Res 2013; 73:3692 - 703; http://dx.doi.org/10.1158/0008-5472.CAN-12-2160; PMID: 23576559
   PubMed Web of Science ®Google Scholar
• Lovly CM, Heuckmann JM, de Stanchina E, Chen H, Thomas RK, Liang C, Pao W. Insights into ALK-driven cancers revealed through development of novel ALK tyrosine kinase inhibitors. Cancer Res 2011; 71:4920 - 31; http://dx.doi.org/10.1158/0008-5472.CAN-10-3879; PMID: 21613408
   PubMed Web of Science ®Google Scholar
• Bresler SC, Wood AC, Haglund EA, Courtright J, Belcastro LT, Plegaria JS, Cole K, Toporovskaya Y, Zhao H, Carpenter EL, et al. Differential inhibitor sensitivity of anaplastic lymphoma kinase variants found in neuroblastoma. Sci Transl Med 2011; 3:108ra114; http://dx.doi.org/10.1126/scitranslmed.3002950; PMID: 22072639
   PubMed Web of Science ®Google Scholar
• Heuckmann JM, Hölzel M, Sos ML, Heynck S, Balke-Want H, Koker M, Peifer M, Weiss J, Lovly CM, Grütter C, et al. ALK mutations conferring differential resistance to structurally diverse ALK inhibitors. Clin Cancer Res 2011; 17:7394 - 401; http://dx.doi.org/10.1158/1078-0432.CCR-11-1648; PMID: 21948233
   PubMed Web of Science ®Google Scholar
• Minkovsky N, Berezov A. BIBW-2992, a dual receptor tyrosine kinase inhibitor for the treatment of solid tumors. Curr Opin Investig Drugs 2008; 9:1336 - 46; PMID: 19037840
   PubMed Web of Science ®Google Scholar
• Chresta CM, Davies BR, Hickson I, Harding T, Cosulich S, Critchlow SE, Vincent JP, Ellston R, Jones D, Sini P, et al. AZD8055 is a potent, selective, and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity. Cancer Res 2010; 70:288 - 98; http://dx.doi.org/10.1158/0008-5472.CAN-09-1751; PMID: 20028854
   PubMed Web of Science ®Google Scholar
• McMahon LP, Choi KM, Lin TA, Abraham RT, Lawrence JC Jr.. The rapamycin-binding domain governs substrate selectivity by the mammalian target of rapamycin. Mol Cell Biol 2002; 22:7428 - 38; http://dx.doi.org/10.1128/MCB.22.21.7428-7438.2002; PMID: 12370290
   PubMed Web of Science ®Google Scholar
• Paglin S, Lee NY, Nakar C, Fitzgerald M, Plotkin J, Deuel B, Hackett N, McMahill M, Sphicas E, Lampen N, et al. Rapamycin-sensitive pathway regulates mitochondrial membrane potential, autophagy, and survival in irradiated MCF-7 cells. Cancer Res 2005; 65:11061 - 70; http://dx.doi.org/10.1158/0008-5472.CAN-05-1083; PMID: 16322256
   PubMed Web of Science ®Google Scholar
• Kinoshita K, Oikawa N, Tsukuda T. Anaplastic lymphoma kinase inhibitors for the treatment of ALK-positive cancers. Annu Rep Med Chem 2012; 47:281 - 93; http://dx.doi.org/10.1016/B978-0-12-396492-2.00019-9
   Web of Science ®Google Scholar
• Liu X, Newton RC, Scherle PA. Development of c-MET pathway inhibitors. Expert Opin Investig Drugs 2011; 20:1225 - 41; http://dx.doi.org/10.1517/13543784.2011.600687; PMID: 21740293
   PubMed Web of Science ®Google Scholar
• Okamoto W, Okamoto I, Arao T, Kuwata K, Hatashita E, Yamaguchi H, Sakai K, Yanagihara K, Nishio K, Nakagawa K. Antitumor action of the MET tyrosine kinase inhibitor crizotinib (PF-02341066) in gastric cancer positive for MET amplification. Mol Cancer Ther 2012; 11:1557 - 64; http://dx.doi.org/10.1158/1535-7163.MCT-11-0934; PMID: 22729845
   PubMed Web of Science ®Google Scholar
• Tanizaki J, Okamoto I, Okamoto K, Takezawa K, Kuwata K, Yamaguchi H, Nakagawa K. MET tyrosine kinase inhibitor crizotinib (PF-02341066) shows differential antitumor effects in non-small cell lung cancer according to MET alterations. J Thorac Oncol 2011; 6:1624 - 31; http://dx.doi.org/10.1097/JTO.0b013e31822591e9; PMID: 21716144
   PubMed Web of Science ®Google Scholar
• Guo A, Villén J, Kornhauser J, Lee KA, Stokes MP, Rikova K, Possemato A, Nardone J, Innocenti G, Wetzel R, et al. Signaling networks assembled by oncogenic EGFR and c-Met. Proc Natl Acad Sci U S A 2008; 105:692 - 7; http://dx.doi.org/10.1073/pnas.0707270105; PMID: 18180459
   PubMed Web of Science ®Google Scholar
• Dulak AM, Gubish CT, Stabile LP, Henry C, Siegfried JM. HGF-independent potentiation of EGFR action by c-Met. Oncogene 2011; 30:3625 - 35; http://dx.doi.org/10.1038/onc.2011.84; PMID: 21423210
   PubMed Web of Science ®Google Scholar
• Zhang YW, Staal B, Essenburg C, Lewis S, Kaufman D, Vande Woude GF. Strengthening context-dependent anticancer effects on non-small cell lung carcinoma by inhibition of both MET and EGFR. Mol Cancer Ther 2013; 12:1429 - 41; http://dx.doi.org/10.1158/1535-7163.MCT-13-0016; PMID: 23720767
   PubMed Web of Science ®Google Scholar
• Yu K, Toral-Barza L, Shi C, Zhang WG, Lucas J, Shor B, Kim J, Verheijen J, Curran K, Malwitz DJ, et al. Biochemical, cellular, and in vivo activity of novel ATP-competitive and selective inhibitors of the mammalian target of rapamycin. Cancer Res 2009; 69:6232 - 40; http://dx.doi.org/10.1158/0008-5472.CAN-09-0299; PMID: 19584280
   PubMed Web of Science ®Google Scholar
• Yu K, Toral-Barza L, Shi C, Zhang WG, Zask A. Response and determinants of cancer cell susceptibility to PI3K inhibitors: combined targeting of PI3K and Mek1 as an effective anticancer strategy. Cancer Biol Ther 2008; 7:307 - 15; http://dx.doi.org/10.4161/cbt.7.2.5334; PMID: 18059185
   PubMed Web of Science ®Google Scholar
• Yu K, Shi C, Toral-Barza L, Lucas J, Shor B, Kim JE, Zhang WG, Mahoney R, Gaydos C, Tardio L, et al. Beyond rapalog therapy: preclinical pharmacology and antitumor activity of WYE-125132, an ATP-competitive and specific inhibitor of mTORC1 and mTORC2. Cancer Res 2010; 70:621 - 31; http://dx.doi.org/10.1158/0008-5472.CAN-09-2340; PMID: 20068177
   PubMed Web of Science ®Google Scholar